NCT00286494 - Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

493

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin and pioglitazone

Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks

DRUG

Alogliptin and pioglitazone

Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks

DRUG

Pioglitazone

Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks

Trial Locations (77)

Unknown

Birmingham

Phoenix

Anaheim

Artesia

Fresno

Mission Viejo

Northridge

Orange

San Diego

Walnut Creek

Colorado Springs

Denver

Norwalk

Washington D.C.

Clearwater

Cocoa Beach

Hollywood

Kissimmee

Longwood

New Port Richey

Ocala

Ocoee

Saint Cloud

Tampa

Lawrenceville

Honolulu

Idaho Falls

Chicago

Avon

Elkhart

Evansville

Lafayette

Erlanger

Baltimore

Sudbury

Chesterfield

St Louis

Omaha

Berlin

Burlington

Charlotte

Hickory

Morehead City

Pinehurst

Wilmington

Winston-Salem

Cincinnati

Dayton

Tulsa

Medford

Lansdale

West Grove

Charleston

Columbia

Simpsonville

Bristol

Cookeville

Milan

Corpus Christi

Dallas

San Antonio

Temple

Texarkana

Burlington

Multiple Cities